Women’s Health Today—May 13, 2026

This biweekly Women’s Health video recap highlights regulatory actions, clinical progress, imaging advances, data releases, partnerships, and oncology research developments.
Dive deeper

In Today’s Newsletter

🧬 Camizestrant ODAC vote setback [1] [US • 30 Apr 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/fda-odac-vote-on-camizestrant-breast-cancer.html
Context: AstraZeneca’s camizestrant plus a CDK4/6 inhibitor is under FDA review for 1L HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation.
Key point: FDA ODAC did not reach a majority vote in favor of benefit-risk, voting 3 to 6, based on SERENA-6 Phase 3 data.
Implication: May influence prescriber choice and payer reviews pending full data.

💉 POHERDY pertuzumab biosimilar approved in Europe [2] [EU • 29 Apr 2026]

https://www.organon.com/news/european-commission-ec-approves-henlius-and-organons-poherdy-pertuzumab-the-first-approved-biosimilar-to-perjeta-pertuzumab-in-europe/
Context: POHERDY (Henlius, Organon; pertuzumab biosimilar) is approved for all indications of reference Perjeta in Europe.
Key point: European Commission granted marketing authorization for POHERDY, described as the first approved pertuzumab biosimilar in Europe.
Implication: Introduces competition that may affect pricing and formulary access.

🔬 99mTc-maraciclatide Phase 2 endometriosis imaging data [3] [UK • 30 Apr 2026]

https://www.prnewswire.com/news-releases/endometriosis-imaging-study-published-in-the-lancet-obstetrics-gynaecology–womens-health-highlights-99mtc-maraciclatide-as-a-promising-diagnostic-and-monitoring-tool-302758770.html
Context: Serac Healthcare and University of Oxford published Phase 2 DETECT data in The Lancet Obstetrics, Gynaecology & Women’s Health.
Key point: 99mTc-maraciclatide imaging showed concordance with surgical findings in 16/19 cases and detected lesions across endometriosis subtypes.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🩺 KARISMA Endoxifen breast-density publication [4] [Sweden • 06 May 2026]

https://investors.atossatherapeutics.com/2026-05-06-Atossa-Therapeutics-Announces-Publication-of-KARISMA-Endoxifen-Trial-Demonstrating-Significant-Reduction-in-Mammographic-Breast-Density-in-Healthy-Premenopausal-Women
Context: KARISMA Endoxifen was a randomized, double-blind, placebo-controlled Phase 2 trial in 240 healthy premenopausal women.
Key point: Atossa reported 1 mg and 2 mg daily oral Endoxifen significantly reduced mammographic breast density versus placebo after six months.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 VEPPANU FDA approval for ESR1-mutated breast cancer [5] [US • 01 May 2026]

https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-fda-approval-veppanu-vepdegestrant-treatment
Context: VEPPANU (Arvinas, Pfizer; vepdegestrant) is an oral PROTAC estrogen receptor degrader.
Key point: FDA approved VEPPANU for adults with ESR1-mutated ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
Implication: May influence prescriber choice and payer reviews pending full data.

🤖 OCRA launches AI-powered gynecologic cancer research exchange [6] [Global • 08 May 2026]

https://www.prnewswire.com/news-releases/ovarian-cancer-research-alliance-launches-community-accelerated-research-exchange-a-global-ai-powered-ecosystem-to-transform-gynecologic-cancer-research-302766415.html
Context: Ovarian Cancer Research Alliance launched the Community Accelerated Research Exchange, powered by AWS infrastructure and AI tools.
Key point: The platform connects patients, researchers, clinicians, and advocates using patient-powered real-world data and shared research environments.
Implication: May expand screening, initiation, and follow-up at scale.

🧫 Amplia and ANZGOG plan PRROSE ovarian cancer study [7] [Australia–New Zealand • 09 May 2026]

https://www.manilatimes.net/2026/05/09/tmt-newswire/globenewswire/amplia-therapeutics-and-australia-new-zealand-gynaecological-oncology-group-anzgog-announce-ovarian-cancer-study/2339859
Context: Amplia Therapeutics and ANZGOG entered an agreement for an investigator-initiated study of narmafotinib in high-grade serous ovarian cancer.
Key point: PRROSE will evaluate narmafotinib plus carboplatin and paclitaxel in about 15–20 patients with poor response to pre-surgery platinum chemotherapy.
Implication: Signals pipeline investment and modality expansion.

Why It Matters

ESR1-mutated breast cancer remains an active innovation area, with a regulatory setback for camizestrant and FDA approval for VEPPANU in the same news cycle. [1][5]
Biosimilar pertuzumab approval in Europe may broaden access and add competitive pressure in HER2-positive breast cancer care. [2]
Endometriosis imaging advances could reduce reliance on invasive diagnosis, especially for superficial peritoneal disease, if Phase 3 confirms Phase 2 findings. [3]
Breast cancer prevention research is moving toward lower-dose endocrine approaches that may balance biomarker impact with tolerability. [4]
Gynecologic cancer research infrastructure is shifting toward real-world data, AI-enabled analysis, and cross-institution collaboration. [6][7]

📚 View the full Women’s health archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Women’s Health news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What happened with AstraZeneca’s camizestrant at FDA ODAC?

FDA ODAC voted 3 to 6 and did not reach majority support for camizestrant plus CDK4/6 inhibitor in 1L HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation. FDA is not bound by the vote. [1]

What is POHERDY, and why is its EU approval notable?

POHERDY (Henlius, Organon; pertuzumab) is a biosimilar to Perjeta. The European Commission approved it for all reference-product indications, and the source describes it as Europe’s first approved pertuzumab biosimilar. [2]

What did the DETECT study suggest about 99mTc-maraciclatide?

The Phase 2 DETECT publication reported that 99mTc-maraciclatide imaging correlated with laparoscopy findings and detected lesions missed by conventional imaging. Larger Phase 3 validation is still needed. [3]

What did Atossa report from KARISMA Endoxifen?

Atossa reported that 1 mg and 2 mg daily oral Endoxifen reduced mammographic breast density versus placebo after six months in healthy premenopausal women. The 1 mg dose had tolerability similar to placebo in the source. [4]

What is VEPPANU approved for?

VEPPANU (vepdegestrant; Arvinas, Pfizer) is FDA-approved for adults with ESR1-mutated ER-positive, HER2-negative advanced or metastatic breast cancer after at least one endocrine therapy line. [5]

What is the PRROSE ovarian cancer study?

PRROSE is an ANZGOG-sponsored study of narmafotinib plus carboplatin and paclitaxel in about 15–20 patients with high-grade serous ovarian cancer and poor response to pre-surgery platinum chemotherapy. [7]

Entities / Keywords

AstraZeneca, camizestrant, SERENA-6, FDA ODAC, CDK4/6 inhibitor, HR-positive breast cancer, HER2-negative breast cancer, ESR1 mutation
Henlius, Organon, POHERDY, pertuzumab, Perjeta, biosimilar, HER2-positive breast cancer, European Commission
Serac Healthcare, University of Oxford, 99mTc-maraciclatide, DETECT, endometriosis, superficial peritoneal endometriosis, αvβ3 integrin
Atossa Therapeutics, Endoxifen, KARISMA Endoxifen, mammographic breast density, breast cancer prevention, Karolinska Institutet
Arvinas, Pfizer, VEPPANU, vepdegestrant, PROTAC, estrogen receptor degrader, VERITAC-2
Ovarian Cancer Research Alliance, OCRA, Community Accelerated Research Exchange, AWS, Living Lab, Discovery Lab, ovarian cancer, uterine cancer
Amplia Therapeutics, ANZGOG, narmafotinib, PRROSE, FAK inhibitor, high-grade serous ovarian cancer, carboplatin, paclitaxel